P-030 First results from the RedirecTT-1 study with teclistamab (tec) + talquetamab (tal) simultaneously targeting BCMA and GPRC5D in patients (pts) with relapsed/refractory multiple myeloma (RRMM)
Year: 2023
Type: conference-abstract
Authors: Hila Magen, Daniel Morillo, Moshe Gatt, Michael Sebag, Kihyun Kim, Chang-Ki Min, Albert Oriol, Enrique Ocio, Sung-Soo Yoon, Maria-Victoria Mateos, Michael Chu, Paula Rodriguez-Otero, Irit Avivi, Yue Guo, Maria Krevvata, Michelle Peterson, Melissa Beelen, Jill Vanak, Arnob Banerjee, Yaël Cohen
Institutions: Tel Aviv University, Xuzhou Medical College, Sheba Medical Center, Affiliated Hospital of Xuzhou Medical College, Hospital Universitario Fundación Jiménez Díaz, Hadassah Medical Center, McGill University Health Centre, McGill University, Samsung Medical Center, Sungkyunkwan University, The Catholic University of Korea Seoul St. Mary's Hospital, Institut Català d'Oncologia, Marqués de Valdecilla University Hospital, Seoul National University, Instituto de Investigación Biomédica de Salamanca, Centro de Investigación del Cáncer, Centro de Investigación Biomédica en Red de Cáncer, Alberta Health Services, Navarre Institute of Health Research, Clinica Universidad de Navarra, Centro de Investigación Médica Aplicada, Tel Aviv Sourasky Medical Center
Language: English
Subfield: Hematology
Field: Medicine
Domain: Health Sciences
Open Access status: closed
OpenAlex ID: W4387003852